{"id":199773,"date":"2024-11-19T15:28:26","date_gmt":"2024-11-19T21:28:26","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/11\/experimental-therapeutic-reduces-advanced-stage-influenza-viral-loads-faster-than-current-therapies-in-preclinical-study"},"modified":"2024-11-19T15:28:26","modified_gmt":"2024-11-19T21:28:26","slug":"experimental-therapeutic-reduces-advanced-stage-influenza-viral-loads-faster-than-current-therapies-in-preclinical-study","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/11\/experimental-therapeutic-reduces-advanced-stage-influenza-viral-loads-faster-than-current-therapies-in-preclinical-study","title":{"rendered":"Experimental therapeutic reduces advanced-stage influenza viral loads faster than current therapies in preclinical study"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/experimental-therapeutic-reduces-advanced-stage-influenza-viral-loads-faster-than-current-therapies-in-preclinical-study2.jpg\"><\/a><\/p>\n<p>Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.<\/p>\n<p>A single intranasal dose of EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating the detectable virus within 24 hours. EV25 also has a window of efficacy of 96 hours postinfection, which is broader than the current standard of care.<\/p>\n<p>A <a href=\"https:\/\/medicalxpress.com\/tags\/research+paper\/\" rel=\"tag\" class=\"\">research paper<\/a> titled \u201cTargeted recruitment of immune effector cells for rapid eradication of <a href=\"https:\/\/medicalxpress.com\/tags\/influenza+virus\/\" rel=\"tag\" class=\"\">influenza virus<\/a> infections\u201d has been <a href=\"https:\/\/pnas.org\/doi\/10.1073\/pnas.2408469121\" target=\"_blank\">published<\/a> in <i>Proceedings of the National Academy of Sciences.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies. A single intranasal dose of EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating the detectable virus [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-199773","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/199773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=199773"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/199773\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=199773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=199773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=199773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}